Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 13/20 | 0.40 |
| ▸ | HTR2C | P28335 | 12/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657294 | 0.88 | PTGDR2 (0.42) | KDM4EALDH1A1ALKBH1HDAC1 | |
| SCHEMBL3748666 | 0.79 | PTGDR2 (0.41) | ALDH1A1ALKBH1HDAC1 | |
| SCHEMBL2661774 | 0.79 | MEN1 (0.47) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2662441 | 0.78 | CA12 (0.40) | HTR2A | |
| SCHEMBL2659657 | 0.77 | CCR2 (0.41) | KDM4EALDH1A1HPGDHSD17B10MME | |
| SCHEMBL3741636 | 0.76 | ALKBH1 (0.35) | HTR2AALKBH1 | |
| SCHEMBL2661546 | 0.75 | MCL1 (0.41) | MAOB | |
| SCHEMBL2661140 | 0.75 | CYP2D6 (0.46) | KDM4EALDH1A1MAOB | |
| SCHEMBL2659965 | 0.74 | PTGDR2 (0.44) | KDM4EALDH1A1ALKBH1HDAC1 | |
| SCHEMBL2662341 | 0.74 | CNR1 (0.41) | KDM4EALDH1A1HPGDHSD17B10MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299115-B2 | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2012-10-30 | — | — | US | disclosed |
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | GCK, PCK1, GCKR | HTR2A 1045/4885HTR2C 1102/4885NPBWR1 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.